Krystal Biotech, Inc. Other Non-Current Liabilities
Krystal Biotech, Inc. (KRYS) had Other Non-Current Liabilities of $7.08 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-03
- 2026-06-30: Other Liabilities, Noncurrent $7.08M.
- 2026-03-31: Other Liabilities, Noncurrent $5.12M.
- 2025-12-31: Other Liabilities, Noncurrent $3.72M.
- 2025-09-30: Other Liabilities, Noncurrent $3.14M.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2026-06-30 | $7.08M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $5.12M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $3.72M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $3.14M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $2.79M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $1.95M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.42M 10-K · filed 2026-02-17 |
| 2024-09-30 | $761.00K 10-Q · filed 2024-11-04 |
| 2024-06-30 | $588.00K 10-Q · filed 2024-08-05 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-19 |
| 2018-12-31 | $294.00K 10-K · filed 2020-03-10 |
| 2018-09-30 | $245.00K 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |